CytoSorbents Corporation announced a 1-for-20 reverse stock split effective September 8, 2026, to increase its stock price and comply with Nasdaq's $1 minimum bid price requirement. The split will reduce the number of shares outstanding from about 63 million to approximately 3.15 million, adjusting the trading price proportionally without changing the company's market value. Shareholders will not need to take action, and fractional shares will be rounded up. This move aims to maintain the company's Nasdaq listing and support its ongoing business in blood purification technologies for critical care.
Sailfish Royalty Corp. announced its third quarterly cash dividend for 2026 at US$0.0375 per common share, payable on October 15, 2026, to shareholders of record as of September 30, 2026. The company emphasized that future dividends depend on its fin...
Tesla is gearing up to reveal more details about its Cybercab, a driverless two-seater robotaxi with no steering wheel or pedals, at an invitation-only event in Austin, Texas. The company has been testing versions of the vehicle with human drivers, b...
Armata Pharmaceuticals published a study detailing the structure and infection mechanism of Ar-KM, a bacteriophage targeting the antibiotic-resistant bacteria Pseudomonas aeruginosa. Using advanced cryo-electron microscopy and other techniques, resea...
Saturn Oil & Gas has renewed its Normal Course Issuer Bid (NCIB) allowing the company to repurchase and cancel up to 12.2 million common shares over the next year. This follows a successful previous buyback program where Saturn repurchased 12 million...
Amber International announced a strategic pivot to building specialized AI agents, launching two products: Ambre for personal finance and MIA for marketing workflows. In Q2 2026, total revenue rose 38.8% quarter-over-quarter to $13.9 million, driven ...
